EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance

Hussein Sabit iD, Borros Arneth iD, Timothy M Pawlik iD, Shaimaa Abdel-Ghany iD, Aysha Ghazy, Rawan M Abdelazeem, Amany Alqosaibi iD, Ibtesam S Al-Dhuayan iD, Jawaher Almulhim, Noof A Alrabiah iD, Ahmed Hashash

Pharmaceuticals · 10.01.2025 · 18 (1) · 75

DOI: 10.3390/ph18010075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 10.01.2025. Verfasst von Hussein Sabit und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza 3237101, Egypt. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent developments in single-cell multi-omics technologies have provided the ability to identify diverse cell types and decipher key components of the tumor microenvironment (TME), leading to important advancements toward a much deeper understanding of how tumor microenvironment heterogeneity contributes to cancer progression and therapeutic resistance. These technologies are able to integrate data from molecular genomic, transcriptomic, proteomics, and metabolomics studies of cells at a single-cell resolution scale that give rise to the full cellular and molecular complexity in the TME. Understanding the complex and sometimes reciprocal relationships among cancer cells, CAFs, immune cells, and ECs has led to novel insights into their immense heterogeneity in functions, which can have important consequences on tumor behavior. In-depth studies have uncovered immune evasion mechanisms, including the exhaustion of T cells and metabolic reprogramming in response to hypoxia from cancer cells. Single-cell multi-omics also revealed resistance mechanisms, such as stromal cell-secreted factors and physical barriers in the extracellular matrix. Future studies examining specific metabolic pathways and targeting approaches to reduce the heterogeneity in the TME will likely lead to better outcomes with immunotherapies, drug delivery, etc., for cancer treatments. Future studies will incorporate multi-omics data, spatial relationships in tumor micro-environments, and their translation into personalized cancer therapies. This review emphasizes how single-cell multi-omics can provide insights into the cellular and molecular heterogeneity of the TME, revealing immune evasion mechanisms, metabolic reprogramming, and stromal cell influences. These insights aim to guide the development of personalized and targeted cancer therapies, highlighting the role of TME diversity in shaping tumor behavior and treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

cancer therapeutic resistanceimmune evasionmetabolic reprogrammingpersonalized cancer therapysingle-cell multi-omicstumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza 3237101, Egypt.
  • Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Hospital of the Universities of Giessen and Marburg (UKGM), Philipps University Marburg, Baldingerstr. 1, 35043 Marburg, Germany.
  • Department of Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH 43210, USA.
  • Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza 3237101, Egypt.
  • Department of Agricultural Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza 3237101, Egypt.
  • Department of Biology, College of Science, Imam Abdulrahman bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia.

ORCID-Profile: Hussein Sabit, Borros Arneth, Timothy M Pawlik, Shaimaa Abdel-Ghany, Amany Alqosaibi, Ibtesam S Al-Dhuayan, Noof A Alrabiah

Zitieren

APA

Sabit, H., Arneth, B., Pawlik, T. M., Abdel-Ghany, S., Ghazy, A., Abdelazeem, R. M., Alqosaibi, A., Al-Dhuayan, I. S., Almulhim, J., Alrabiah, N. A., & Hashash, A. (2025). Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance. Pharmaceuticals, 18(1), 75. https://doi.org/10.3390/ph18010075

Vancouver

Sabit H, Arneth B, Pawlik TM, Abdel-Ghany S, Ghazy A, Abdelazeem RM, et al. Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance. Pharmaceuticals. 2025;18(1):75. doi:10.3390/ph18010075

BibTeX
@article{Sabit2025,
  author = {Sabit, Hussein and Arneth, Borros and Pawlik, Timothy M and Abdel-Ghany, Shaimaa and Ghazy, Aysha and Abdelazeem, Rawan M and Alqosaibi, Amany and Al-Dhuayan, Ibtesam S and Almulhim, Jawaher and Alrabiah, Noof A and Hashash, Ahmed},
  title = {Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {75},
  doi = {10.3390/ph18010075}
}
Kostenlos starten →